Benzinga's Top Ratings Upgrades, Downgrades For May 23, 2023

Upgrades

MoffettNathanson upgraded the previous rating for Zoom Video Communications Inc ZM from Underperform to Market Perform. Zoom Video Comms earned $1.16 in the first quarter, compared to $1.03 in the year-ago quarter. At the moment, the stock has a 52-week-high of $124.05 and a 52-week-low of $60.45. Zoom Video Comms closed at $71.41 at the end of the last trading period.

Evercore ISI Group upgraded the previous rating for CCC Intelligent Solutions Holdings Inc CCCS from In-Line to Outperform. For the first quarter, CCC Intelligent Solutions had an EPS of $0.07, compared to year-ago quarter EPS of $0.08. The current stock performance of CCC Intelligent Solutions shows a 52-week-high of $10.19 and a 52-week-low of $8.20. Moreover, at the end of the last trading period, the closing price was at $9.92.

According to HSBC, the prior rating for Chevron Corp CVX was changed from Hold to Buy. For the first quarter, Chevron had an EPS of $3.55, compared to year-ago quarter EPS of $3.36. At the moment, the stock has a 52-week-high of $189.66 and a 52-week-low of $132.54. Chevron closed at $152.44 at the end of the last trading period.

According to Goldman Sachs, the prior rating for Quanterix Corp QTRX was changed from Neutral to Buy. For the first quarter, Quanterix had an EPS of $0.16, compared to year-ago quarter EPS of $0.49. At the moment, the stock has a 52-week-high of $20.20 and a 52-week-low of $6.32. Quanterix closed at $19.23 at the end of the last trading period.

For Myriad Genetics Inc MYGN, Goldman Sachs upgraded the previous rating of Sell to Buy. Myriad Genetics earned $0.21 in the first quarter, compared to $0.03 in the year-ago quarter. The stock has a 52-week-high of $28.17 and a 52-week-low of $13.92. At the end of the last trading period, Myriad Genetics closed at $20.07.

For Greenhill & Co Inc GHL, Keefe, Bruyette & Woods upgraded the previous rating of Underperform to Market Perform. Greenhill & Co earned $1.27 in the first quarter, compared to $0.66 in the year-ago quarter. The current stock performance of Greenhill & Co shows a 52-week-high of $14.85 and a 52-week-low of $5.70. Moreover, at the end of the last trading period, the closing price was at $14.66.

See all analyst ratings upgrades.

Downgrades

For Rain Oncology Inc RAIN, Citigroup downgraded the previous rating of Buy to Neutral. Rain Oncology earned $0.56 in the first quarter, compared to $0.66 in the year-ago quarter. The stock has a 52-week-high of $14.48 and a 52-week-low of $1.11. At the end of the last trading period, Rain Oncology closed at $1.22.

Citigroup downgraded the previous rating for Integra Lifesciences Holdings Corp IART from Neutral to Sell. For the first quarter, Integra Lifesciences had an EPS of $0.74, compared to year-ago quarter EPS of $0.74. The stock has a 52-week-high of $62.94 and a 52-week-low of $40.68. At the end of the last trading period, Integra Lifesciences closed at $50.72.

Piper Sandler downgraded the previous rating for VectivBio Holding AG VECT from Overweight to Neutral. None

For VectivBio Holding AG VECT, SVB Leerink downgraded the previous rating of Outperform to Market Perform. None

For Maravai LifeSciences Holdings Inc MRVI, Credit Suisse downgraded the previous rating of Outperform to Neutral. In the first quarter, Maravai LifeSciences showed an EPS of $0.03, compared to $0.54 from the year-ago quarter. The current stock performance of Maravai LifeSciences shows a 52-week-high of $35.82 and a 52-week-low of $11.89. Moreover, at the end of the last trading period, the closing price was at $13.60.

According to Needham, the prior rating for Intercept Pharmaceuticals Inc ICPT was changed from Buy to Hold. For the first quarter, Intercept Pharma had an EPS of $0.77, compared to year-ago quarter EPS of $0.58. The stock has a 52-week-high of $21.86 and a 52-week-low of $9.21. At the end of the last trading period, Intercept Pharma closed at $9.53.

RBC Capital downgraded the previous rating for Wheaton Precious Metals Corp WPM from Outperform to Sector Perform. In the first quarter, Wheaton Precious Metals showed an EPS of $0.23, compared to $0.35 from the year-ago quarter. The stock has a 52-week-high of $52.76 and a 52-week-low of $28.63. At the end of the last trading period, Wheaton Precious Metals closed at $47.79.

JonesTrading downgraded the previous rating for Rain Oncology Inc RAIN from Buy to Hold. In the first quarter, Rain Oncology showed an EPS of $0.56, compared to $0.66 from the year-ago quarter. The stock has a 52-week-high of $14.48 and a 52-week-low of $1.11. At the end of the last trading period, Rain Oncology closed at $1.22.

For Rain Oncology Inc RAIN, HC Wainwright & Co. downgraded the previous rating of Buy to Neutral. In the first quarter, Rain Oncology showed an EPS of $0.56, compared to $0.66 from the year-ago quarter. The stock has a 52-week-high of $14.48 and a 52-week-low of $1.11. At the end of the last trading period, Rain Oncology closed at $1.22.

Piper Sandler downgraded the previous rating for Rain Oncology Inc RAIN from Overweight to Neutral. In the first quarter, Rain Oncology showed an EPS of $0.56, compared to $0.66 from the year-ago quarter. The current stock performance of Rain Oncology shows a 52-week-high of $14.48 and a 52-week-low of $1.11. Moreover, at the end of the last trading period, the closing price was at $1.22.

JMP Securities downgraded the previous rating for Greenhill & Co Inc GHL from Market Outperform to Market Perform. For the first quarter, Greenhill & Co had an EPS of $1.27, compared to year-ago quarter EPS of $0.66. The current stock performance of Greenhill & Co shows a 52-week-high of $14.85 and a 52-week-low of $5.70. Moreover, at the end of the last trading period, the closing price was at $14.66.

According to Oppenheimer, the prior rating for Rain Oncology Inc RAIN was changed from Outperform to Perform. In the first quarter, Rain Oncology showed an EPS of $0.56, compared to $0.66 from the year-ago quarter. At the moment, the stock has a 52-week-high of $14.48 and a 52-week-low of $1.11. Rain Oncology closed at $1.22 at the end of the last trading period.

For Rain Oncology Inc RAIN, EF Hutton downgraded the previous rating of Buy to Hold. For the first quarter, Rain Oncology had an EPS of $0.56, compared to year-ago quarter EPS of $0.66. The stock has a 52-week-high of $14.48 and a 52-week-low of $1.11. At the end of the last trading period, Rain Oncology closed at $1.22.

Credit Suisse downgraded the previous rating for VectivBio Holding AG VECT from Outperform to Neutral. None

See all analyst ratings downgrades.

Initiations

JP Morgan initiated coverage on United States Steel Corp X with a Neutral rating. The price target for United States Steel is set to $24.00. United States Steel earned $0.77 in the first quarter, compared to $3.05 in the year-ago quarter. The stock has a 52-week-high of $31.55 and a 52-week-low of $16.42. At the end of the last trading period, United States Steel closed at $21.70.

For Precigen Inc PGEN, JP Morgan initiated coverage, by setting the current rating at Neutral. In the first quarter, Precigen showed an EPS of $0.10, compared to $0.10 from the year-ago quarter. At the moment, the stock has a 52-week-high of $2.90 and a 52-week-low of $0.81. Precigen closed at $1.31 at the end of the last trading period.

With a Buy rating, CL King initiated coverage on Silk Road Medical Inc SILK. The price target seems to have been set at $47.00 for Silk Road Medical. For the first quarter, Silk Road Medical had an EPS of $0.43, compared to year-ago quarter EPS of $0.48. At the moment, the stock has a 52-week-high of $58.04 and a 52-week-low of $27.45. Silk Road Medical closed at $31.46 at the end of the last trading period.

JP Morgan initiated coverage on GrafTech International Ltd EAF with a Neutral rating. For the first quarter, GrafTech International had an EPS of $0.02, compared to year-ago quarter EPS of $0.48. At the moment, the stock has a 52-week-high of $9.27 and a 52-week-low of $3.75. GrafTech International closed at $4.57 at the end of the last trading period.

With a Buy rating, CL King initiated coverage on Axonics Inc AXNX. The price target seems to have been set at $75.00 for Axonics. In the first quarter, Axonics showed an EPS of $0.19, compared to $0.50 from the year-ago quarter. At the moment, the stock has a 52-week-high of $79.88 and a 52-week-low of $47.30. Axonics closed at $51.61 at the end of the last trading period.

With a Buy rating, B of A Securities initiated coverage on TopBuild Corp BLD. The price target seems to have been set at $225.00 for TopBuild. TopBuild earned $4.36 in the first quarter, compared to $3.50 in the year-ago quarter. The current stock performance of TopBuild shows a 52-week-high of $227.08 and a 52-week-low of $140.93. Moreover, at the end of the last trading period, the closing price was at $209.72.

JP Morgan initiated coverage on Steel Dynamics Inc STLD with an Underweight rating. The price target for Steel Dynamics is set to $82.00. For the first quarter, Steel Dynamics had an EPS of $4.01, compared to year-ago quarter EPS of $6.02. The current stock performance of Steel Dynamics shows a 52-week-high of $136.46 and a 52-week-low of $62.44. Moreover, at the end of the last trading period, the closing price was at $97.19.

With an Underweight rating, JP Morgan initiated coverage on Nucor Corp NUE. The price target seems to have been set at $130.00 for Nucor. For the first quarter, Nucor had an EPS of $4.45, compared to year-ago quarter EPS of $7.67. The stock has a 52-week-high of $182.68 and a 52-week-low of $100.15. At the end of the last trading period, Nucor closed at $139.96.

With a Neutral rating, JP Morgan initiated coverage on Cleveland-Cliffs Inc CLF. The price target seems to have been set at $18.00 for Cleveland-Cliffs. Cleveland-Cliffs earned $0.11 in the first quarter, compared to $1.71 in the year-ago quarter. At the moment, the stock has a 52-week-high of $24.65 and a 52-week-low of $11.82. Cleveland-Cliffs closed at $14.87 at the end of the last trading period.

Baird initiated coverage on Chimerix Inc CMRX with an Outperform rating. The price target for Chimerix is set to $7.00. Chimerix earned $0.24 in the first quarter, compared to $0.28 in the year-ago quarter. At the moment, the stock has a 52-week-high of $2.89 and a 52-week-low of $1.09. Chimerix closed at $1.40 at the end of the last trading period.

See all analyst ratings initiations.